The insulin resistance improvement drug market is projected to grow from USD 10.3 billion in 2026 to USD 23.1 billion by 2036, at a CAGR of 8.4%. Insulin sensitizers (TZDs) will dominate with a 28.0% market share, while type 2 diabetes will lead the therapeutic applications segment with a 54.0% share.